In practice this is just fundamentally untrue. Research oncologists frequently tout their pipeline drugs while in different phases and trails prior to approval. It's not merely the general public who is unaware which is understandable, but oncologists, those in the this field of medicine and research are unaware for the most part. I can tell you as a fact this is quite unusual for a drug that has shown this much promise with such a low side effect profile.